Short Courses | Day 1 | Day 2 | Day 3 | Download Brochure
Pre-Conference Short Courses*
TUESDAY, FEBRUARY 2
9:00 AM – 12:00 PM
(SC1) APPLYING NEXT GENERATION SEQUENCING TECHNOLOGIES TO RESEARCH
Introduction to New Technologies and Application in Research
Course Moderator:
Stanley Gloss, Founding Partner & Managing Director, BioTeam, Inc.
Technologies for next generation sequencing are accelerating at a rapid pace. This short course will help to keep you up-to-date on the newest options for DNA sequencing, and the tools to manage the data. The major new advantages will be showcased in the latest platforms, and strategies for managing the data to turn it into useful information will be demonstrated by leaders in the field.
• Technologies for newest platforms next generation sequencing
• Strategies and tools for managing data
• Demonstration of how tools can be applied to research
9:00 Introduction
Stanley Gloss, Founding Partner & Managing Director, BioTeam, Inc.
9:10 Next-Gen Sequence Assembly and Cloud Computing
Francisco M. De La Vega, D.Sc., Distinguished Scientific Fellow, Computational Genomics Research, Genetics Systems R&D, Life Technologies
10:00 Using Wikis for Managing Next-Gen Sequencing Data
Giles Day, Senior Director, BBC Informatics, Pfizer Biotherapeutics & Bioinnovation Center
10:50 Refreshment Break
11:00 Emerging 3rd Generation Sequencing Technologies
Dr. Ronald W. Davis, Professor, Biochemistry & Genetics and Director, Stanford Genome Technology Center, Stanford University
11:50 Q&A and Wrap-up
Stanley Gloss, Founding Partner & Managing Director, BioTeam, Inc.
12:00pm End of Short Course
(SC2) One Case Study In Breast Cancer- Three Perspectives
Illustrating Current Challenges in Personalized Medicine
Moderator: Michael Liebman, Ph.D., Managing Director, Strategic Medicine, Inc.
Breast cancer remains enigmatic- the headlines claim fewer deaths, yet there are still significant problems in establishing the optimal treatment for each patient. Breast cancer is an example where excellent treatments exist, e.g. herceptin and aromatase inhibitors, and companion diagnostics have been developed, yet only 30% of patients respond to these treatments.
This case study will illustrate the complexity of the disease and how both the therapy and diagnostic are being advanced to improve the treatment of patients. An expanded view of patient management will show how to improve the decision process to know who requires treatment and will respond best to current treatments and those in the pipeline. The payer perspective will be considered when weighing the anticipated results of reimbursing for diagnostics . A model will be described that has been created to understand the limitations of treatment protocols and to optimize and tailor treatments and resources.
Introduction to the Case Study
Michael Liebman, Ph.D., Managing Director, Strategic Medicine, Inc.
Clinical Perspective
Laura J. Esserman, Professor, Surgery, University of California, San Francisco Medical Center
Developing the Her2/Neu Test as a Companion Diagnostic
Tracey Colpitts, Ph.D., Manager, Abbott Molecular
Mammoprint-the Next Generation of Breast Cancer Diagnostics
Laura Vantveer, Visiting Professor from the Netherlands (invited)
Where Do We Go From Here?
Michael Liebman, Ph.D.
*Separate Registration Required.
Short Courses | Day 1 | Day 2 | Day 3 | Download Brochure